Article Information
- Received January 28, 2022
- Accepted February 2, 2022
- Published online February 15, 2022.
Author Information
- Madhu Nath1,*,
- Zachary B. Sluzala1,*,
- Ashutosh S. Phadte1,2,*,
- Yang Shan1,
- Angela M. Myers1 and
- Patrice E. Fort1,3
- 1Department of Ophthalmology and Visual Sciences, University of Michigan, Ann Arbor, MI 48105
- 2Currently in Department of Biochemistry and Molecular Biology, Thomas Jefferson University, Philadelphia, PA 19107
- 3Department of Molecular and Integrative Physiology, University of Michigan, Ann Arbor, MI 48105
- Correspondence should be addressed to Patrice E. Fort at patricef{at}umich.edu.
Author contributions
Author contributions: P.E.F. designed research; M.N., Z.B.S., A.S.P., Y.S., and A.M.M. performed research; P.E.F. and A.M.M. contributed unpublished reagents/analytic tools; P.E.F., M.N., Z.B.S., A.P., Y.S., and A.M.M. analyzed data; P.E.F., M.N., Z.B.S., A.S.P., Y.S., and A.M.M. wrote the paper.
Disclosures
P.E.F. has intellectual property interests and is listed as inventor on a patent for the use of CryAA as a retinal neuroprotective treatment. All other authors declare no competing financial interests.
This work was supported by the National Eye Institute Grant EY020895, the National Institutes of Health (NIH) Grant P30EY007003 (Core Grant for Vision Research at the University of Michigan), the NIH Grant P30DK020572 (Michigan Diabetes Research Center), Research to Prevent Blindness, and the Lichter Award.
↵* M.N., Z.B.S., and A.S.P. are equal contributors and co-first authors.
Funding
HHS | NIH | National Eye Institute (NEI)
EY020895; P30EY007003HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
P30DK020572Research to Prevent Blindness (RPB)
N/A
Other Version
- You are viewing the most recent version of this article.
- previous version (February 15, 2022).
Article usage
In this issue
